ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Rating of “Buy” by Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been assigned a consensus recommendation of “Buy” from the six research firms that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of equities analysts have weighed in on the stock. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They set an “outperform” rating and a $15.00 price target for the company. Chardan Capital reissued a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research note on Friday, March 14th. HC Wainwright raised their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, March 14th. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $1.52 on Friday. The business’s fifty day moving average is $2.11 and its two-hundred day moving average is $2.60. ProQR Therapeutics has a 52 week low of $1.50 and a 52 week high of $4.62. The firm has a market cap of $159.92 million, a P/E ratio of -4.75 and a beta of 0.24.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors have recently added to or reduced their stakes in PRQR. Jane Street Group LLC acquired a new stake in ProQR Therapeutics in the 4th quarter valued at approximately $30,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $32,000. Alpine Global Management LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $39,000. Two Sigma Securities LLC acquired a new stake in ProQR Therapeutics in the fourth quarter valued at $40,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth about $54,000. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).